Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition - Proactive Investors USA & Canada

Zynerba launches the Phase 2 trial of its Zygel CBD gel to treat 22q genetic condition  Proactive Investors USA & Canada

Zynerba Pharmaceuticals (NASDAQ:ZYNE) - The disorder is caused by a small missing piece of the 22nd chromosome that can affect every system in the body.



Comments

Popular posts from this blog

Different types of doctors in South Africa and their salaries 2022 - Briefly

Ebstein's Anomaly: Symptoms, Causes, and Treatments - Verywell Health

Internal vs. Family Medicine: Who's Who in Primary Care - Avera Health